Jazz Pharmaceuticals price target raised to $87 from $76 at Lazard Capital Lazard Capital raised its price target fort Jazz Pharmaceuticals citing expectations for robust Xyrem revenue growth and keeps a Buy rating on the stock.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Jazz Pharmaceuticals executing on all cylinders, says Stifel Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.